Action of lycurim and pyrazofurin on hepatoma 3924A cells in culture

J. Ban, E. Oláh, G. Weber

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this study was to test for a possible synergism in the antitumor action of the antimetabolite pyrazofurin (PF) and the alkylating agent lycurim (LY) [1,4-di-(2'-mesyloxy-ethylamino)-1,4-dideoxy-m-erythritol dimethylsulfonate] on proliferating and resting rat hepatoma 3924A cells in tissue culture. Earlier studies showed that PF killed hepatoma cells only in the logarithmic phase of growth as determined by colony-forming ability. Now we report that LY killed hepatoma cells in both the exponential and plateau phases. Treatment of cultures in each phase for 1 or 2 hrs resulted in threshold exponential type dose-response curves, yielding D(o) values of 3 and 1 μM, respectively. LY is a cycle-specific drug, although fluctuations in cell age-dependent survival were also demonstrated. In synchronized cultures, cells were most sensitive to 0.1 μM LY in early G1 phase, but in higher concentration (5 μM), LY killed the cells during the entire cell cycle, especially in G1, early and mid S phases, and M phase. Lycurim and PF given together in their IC50 concentrations (0.016 and 0.085 μM, respectively) yielded synergistic cell kill in 7-day treatment of proliferating cultures. Two-hour treatment of exponentially growing cells with LY and PF at their IC50 concentrations (1 and 20 μM, respectively) also yielded synergistic killing action, but in plateau-phase cells only summation was observed. Synergistic activity of LY and PF in hepatoma 3924A cells was dependent on drug concentration and incubation time.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalCancer Treatment Reports
Volume66
Issue number2
Publication statusPublished - 1982

Fingerprint

pyrazofurin
ritrosulfan
Hepatocellular Carcinoma
Cell Culture Techniques
Inhibitory Concentration 50
Erythritol
Methyl Methanesulfonate
Antimetabolites
Alkylating Agents
G1 Phase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Action of lycurim and pyrazofurin on hepatoma 3924A cells in culture. / Ban, J.; Oláh, E.; Weber, G.

In: Cancer Treatment Reports, Vol. 66, No. 2, 1982, p. 343-349.

Research output: Contribution to journalArticle

@article{85776e851fac4d6b8c5e01c1933902d0,
title = "Action of lycurim and pyrazofurin on hepatoma 3924A cells in culture",
abstract = "The purpose of this study was to test for a possible synergism in the antitumor action of the antimetabolite pyrazofurin (PF) and the alkylating agent lycurim (LY) [1,4-di-(2'-mesyloxy-ethylamino)-1,4-dideoxy-m-erythritol dimethylsulfonate] on proliferating and resting rat hepatoma 3924A cells in tissue culture. Earlier studies showed that PF killed hepatoma cells only in the logarithmic phase of growth as determined by colony-forming ability. Now we report that LY killed hepatoma cells in both the exponential and plateau phases. Treatment of cultures in each phase for 1 or 2 hrs resulted in threshold exponential type dose-response curves, yielding D(o) values of 3 and 1 μM, respectively. LY is a cycle-specific drug, although fluctuations in cell age-dependent survival were also demonstrated. In synchronized cultures, cells were most sensitive to 0.1 μM LY in early G1 phase, but in higher concentration (5 μM), LY killed the cells during the entire cell cycle, especially in G1, early and mid S phases, and M phase. Lycurim and PF given together in their IC50 concentrations (0.016 and 0.085 μM, respectively) yielded synergistic cell kill in 7-day treatment of proliferating cultures. Two-hour treatment of exponentially growing cells with LY and PF at their IC50 concentrations (1 and 20 μM, respectively) also yielded synergistic killing action, but in plateau-phase cells only summation was observed. Synergistic activity of LY and PF in hepatoma 3924A cells was dependent on drug concentration and incubation time.",
author = "J. Ban and E. Ol{\'a}h and G. Weber",
year = "1982",
language = "English",
volume = "66",
pages = "343--349",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Action of lycurim and pyrazofurin on hepatoma 3924A cells in culture

AU - Ban, J.

AU - Oláh, E.

AU - Weber, G.

PY - 1982

Y1 - 1982

N2 - The purpose of this study was to test for a possible synergism in the antitumor action of the antimetabolite pyrazofurin (PF) and the alkylating agent lycurim (LY) [1,4-di-(2'-mesyloxy-ethylamino)-1,4-dideoxy-m-erythritol dimethylsulfonate] on proliferating and resting rat hepatoma 3924A cells in tissue culture. Earlier studies showed that PF killed hepatoma cells only in the logarithmic phase of growth as determined by colony-forming ability. Now we report that LY killed hepatoma cells in both the exponential and plateau phases. Treatment of cultures in each phase for 1 or 2 hrs resulted in threshold exponential type dose-response curves, yielding D(o) values of 3 and 1 μM, respectively. LY is a cycle-specific drug, although fluctuations in cell age-dependent survival were also demonstrated. In synchronized cultures, cells were most sensitive to 0.1 μM LY in early G1 phase, but in higher concentration (5 μM), LY killed the cells during the entire cell cycle, especially in G1, early and mid S phases, and M phase. Lycurim and PF given together in their IC50 concentrations (0.016 and 0.085 μM, respectively) yielded synergistic cell kill in 7-day treatment of proliferating cultures. Two-hour treatment of exponentially growing cells with LY and PF at their IC50 concentrations (1 and 20 μM, respectively) also yielded synergistic killing action, but in plateau-phase cells only summation was observed. Synergistic activity of LY and PF in hepatoma 3924A cells was dependent on drug concentration and incubation time.

AB - The purpose of this study was to test for a possible synergism in the antitumor action of the antimetabolite pyrazofurin (PF) and the alkylating agent lycurim (LY) [1,4-di-(2'-mesyloxy-ethylamino)-1,4-dideoxy-m-erythritol dimethylsulfonate] on proliferating and resting rat hepatoma 3924A cells in tissue culture. Earlier studies showed that PF killed hepatoma cells only in the logarithmic phase of growth as determined by colony-forming ability. Now we report that LY killed hepatoma cells in both the exponential and plateau phases. Treatment of cultures in each phase for 1 or 2 hrs resulted in threshold exponential type dose-response curves, yielding D(o) values of 3 and 1 μM, respectively. LY is a cycle-specific drug, although fluctuations in cell age-dependent survival were also demonstrated. In synchronized cultures, cells were most sensitive to 0.1 μM LY in early G1 phase, but in higher concentration (5 μM), LY killed the cells during the entire cell cycle, especially in G1, early and mid S phases, and M phase. Lycurim and PF given together in their IC50 concentrations (0.016 and 0.085 μM, respectively) yielded synergistic cell kill in 7-day treatment of proliferating cultures. Two-hour treatment of exponentially growing cells with LY and PF at their IC50 concentrations (1 and 20 μM, respectively) also yielded synergistic killing action, but in plateau-phase cells only summation was observed. Synergistic activity of LY and PF in hepatoma 3924A cells was dependent on drug concentration and incubation time.

UR - http://www.scopus.com/inward/record.url?scp=0020048906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020048906&partnerID=8YFLogxK

M3 - Article

C2 - 6895716

AN - SCOPUS:0020048906

VL - 66

SP - 343

EP - 349

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -